Scholarlink

Background <p>Low skeletal muscle mass is associated with adverse cancer outcomes and is a key diagnostic criterion for malnutrition in the Global Leadership Initiative on Malnutrition, emphasizing the importance of muscle mass assessment. This study aimed to establish sex-specific cutoff values for skeletal/psoas muscle mass index (SMI/PMI), calculated from computed tomography, in cancer patients for predicting prognosis.</p> Methods <p>In this multicenter cohort study, preoperative SMI and PMI were analyzed in patients with gastric cancer who underwent gastrectomy without preoperative therapy between 2011 and 2016. Using 80% of the cases as a training set, sex-specific cutoffs for overall survival (OS) were determined via the optimal stratification method, adjusted for age and stage. The remaining 20% were used to validate OS differences between high and low muscle-mass groups.</p> Results <p>Of 3841 registered patients from 17 hospitals, 3797 were analyzed. Spline plots showed a strong association between lower muscle mass and worse OS in males, but a weaker association in females. The SMI cutoffs were 40 cm<sup>2</sup>/m<sup>2</sup> (males) and 31 cm<sup>2</sup>/m<sup>2</sup> (females); PMI cutoffs were 3.7 cm<sup>2</sup>/m<sup>2</sup> (males) and 2.9 cm<sup>2</sup>/m<sup>2</sup> (females). In the validation set, low SMI and PMI were significantly associated with poor OS in males. In females, only PMI remained significant; body mass index better stratified prognosis than muscle indices.</p> Conclusions <p>The proposed cutoffs may facilitate the early identification of muscle loss or malnutrition, supporting timely intervention. The observed sex differences highlight the necessity to develop sex-specific strategies for nutritional and muscle mass management during cancer treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Defining Low Muscle Mass in Cancer Patients: Sex-Specific Computed Tomography-Derived Cutoff Values and Survival Impact—A Multicenter Cohort Study

  • 期刊论文

  • 发表日期：

    2025年9月19日

查看全文
  • Kazuyoshi Yamamoto,
  • Yukinori Kurokawa,
  • Satoshi Hattori,
  • Yoshiro Yukawa,
  • Takeshi Omori,
  • Ryota Matsui,
  • Daisuke Ichikawa,
  • Yoshitomo Yanagimoto,
  • Takashi Oshima,
  • Takashi Kamei,
  • Hiroya Takeuchi,
  • Yoshihiro Nabeya,
  • Masaki Kaibori,
  • Naoki Hiki,
  • Hidetoshi Eguchi,
  • Yuichiro Doki

摘要

Background

Low skeletal muscle mass is associated with adverse cancer outcomes and is a key diagnostic criterion for malnutrition in the Global Leadership Initiative on Malnutrition, emphasizing the importance of muscle mass assessment. This study aimed to establish sex-specific cutoff values for skeletal/psoas muscle mass index (SMI/PMI), calculated from computed tomography, in cancer patients for predicting prognosis.

Methods

In this multicenter cohort study, preoperative SMI and PMI were analyzed in patients with gastric cancer who underwent gastrectomy without preoperative therapy between 2011 and 2016. Using 80% of the cases as a training set, sex-specific cutoffs for overall survival (OS) were determined via the optimal stratification method, adjusted for age and stage. The remaining 20% were used to validate OS differences between high and low muscle-mass groups.

Results

Of 3841 registered patients from 17 hospitals, 3797 were analyzed. Spline plots showed a strong association between lower muscle mass and worse OS in males, but a weaker association in females. The SMI cutoffs were 40 cm2/m2 (males) and 31 cm2/m2 (females); PMI cutoffs were 3.7 cm2/m2 (males) and 2.9 cm2/m2 (females). In the validation set, low SMI and PMI were significantly associated with poor OS in males. In females, only PMI remained significant; body mass index better stratified prognosis than muscle indices.

Conclusions

The proposed cutoffs may facilitate the early identification of muscle loss or malnutrition, supporting timely intervention. The observed sex differences highlight the necessity to develop sex-specific strategies for nutritional and muscle mass management during cancer treatment.